Alvotech (ALVO)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
ALVO
Alvotech
$3.53
+13.87%
HEALTHCARE · Cap: $1.19B
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.25
-2.82%
HEALTHCARE · Cap: $55.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 801568% more annual revenue ($4.51T vs $562.04M). TAK leads profitability with a -3.4% profit margin vs -14.4%. TAK earns a higher WallStSmart Score of 57/100 (C).
ALVO
Avoid18
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.6%
Fair Value
$21.62
Current Price
$3.53
$18.09 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Large-cap with strong market position
Areas to Watch
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Revenue declined 20.2%
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALVO
The strongest argument for ALVO centers on Debt/Equity.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.
Bear Case : ALVO
The primary concerns for ALVO are Market Cap, Return on Equity, Piotroski F-Score.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
ALVO carries more volatility with a beta of 0.19 — expect wider price swings.
TAK is growing revenue faster at 3.9% — sustainability is the question.
ALVO generates stronger free cash flow (-107M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (57/100 vs 18/100). ALVO offers better value entry with a 77.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alvotech
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?